Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy

Markkanen, Johanna E.; Rissanen, Tuomas T.; Kivelä, Antti; Ylä‐Herttuala, Seppo

doi:10.1016/j.cardiores.2004.10.030

Cited by 77 publications

(57 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, it is highly possible that epicardium prevents vascular network formation between the host CMs and MCSs. Furthermore, arteriogenesis may be necessary to use newly formed vessels effectively (52). Coronary artery bypass graft may be the answer.…”

Section: Function Of Mcssmentioning

confidence: 99%

Myocardial cell sheet therapy and cardiac function

Fujita

Itabashi

Seki

et al. 2012

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Heart failure (HF) is the leading cause of death in developed countries. Regenerative medicine has the potential to drastically improve treatment for advanced HF. Stem cell-based medicine has received attention as a promising candidate therapy over the past decade; however, it has not yet realized this potential in terms of reliability. The cell sheet is an innovative technology for constructing aligned graft cells, and several cell sources have been investigated for making a feasible cell sheet. The most representative thus far is skeletal myoblast, although such cells raise the issue of arrhythmogenicity. Regenerative cardiomyocytes (CMs) derived from pluripotent stem cells (PSCs), such as embryonic stem cells or induced PSCs, are the most promising, because a myocardial cell sheet (MCS) constructed with regenerative CMs can potentially enable contraction recovery and electromechanical coupling with host CMs. The functional outcomes of experimental MCS are reduction of ventricular wall stress and paracrine effects rather than contraction recovery. Several technical obstacles still hamper the clinical application of MCSs, with graft survival the most pivotal issue. Ischemia, apoptosis, inflammation, and immune response can all cause graft cell death, and a stable blood supply to the MCS is critical for successful engraftment. Ventricular tachycardia must also be considered in any myocardial cell therapy, and multiple layering of MCS (>3 layers) is necessary to reconstruct human myocardium. Innervation is also a potential issue. The future application of myocardial cell therapy with MCS for advanced HF depends on resolving these difficulties.

show abstract

Section: Function Of Mcssmentioning

confidence: 99%

Myocardial cell sheet therapy and cardiac function

Fujita

Itabashi

Seki

et al. 2012

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…Gene therapy is a rapidly evolving field in cardiovascular medicine. This technology allows for the correction of functional gene loss and enables the expression of a therapeutic gene in a target tissue (52). Nevertheless, gene therapy studies continue to be plagued by suboptimal delivery of genes, poor survival of cells carrying the therapeutic gene(s), and the inability to evaluate the levels of gene expression in vivo (28).…”

Section: Applications Of Bli In Cardiovascular Researchmentioning

confidence: 99%

In vivo bioluminescence for tracking cell fate and function

Almeida¹,

Rappard

2011

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Tracking the fate and function of cells in vivo is paramount for the development of rational therapies for cardiac injury. Bioluminescence imaging (BLI) provides a means for monitoring physiological processes in real time, ranging from cell survival to gene expression to complex molecular processes. In mice and rats, BLI provides unmatched sensitivity because of the absence of endogenous luciferase expression in mammalian cells and the low background luminescence emanating from animals. In the field of stem cell therapy, BLI provides an unprecedented means to monitor the biology of these cells in vivo, giving researchers a greater understanding of their survival, migration, immunogenicity, and potential tumorigenicity in a living animal. In addition to longitudinal monitoring of cell survival, BLI is a useful tool for semiquantitative measurements of gene expression in vivo, allowing a better optimization of drug and gene therapies. Overall, this technology not only enables rapid, reproducible, and quantitative monitoring of physiological processes in vivo but also can measure the influences of therapeutic interventions on the outcome of cardiac injuries.

show abstract

“…Markkanen et al reviews also that combined use of growth-factors or of factors that are capable of up-regulating other factors (e.g. HIF-1) will improve collateral vessel growth in case of IHD [70]. The potential use of miRNAs could also be a strategy for IHD treatment.…”

Section: Possible Targets Of Ischemic Heart-disease (Ihd) Therapymentioning

confidence: 99%